{(E)-4-[((R)-1-{[(R)-1-(N',N'-Dimethyl-hydrazinocarbonyl)-2-thiophen-2-yl-ethyl]-methyl-carbamoyl}-2-naphthalen-2-yl-ethyl)-methyl-carbamoyl]-1,1-dimethyl-but-3-enyl}-carbamic acid tert-butyl ester | 232615-24-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: {(E)-4-[((R)-1-{[(R)-1-(N',N'-Dimethyl-hydrazinocarbonyl)-2-thiophen-2-yl-ethyl]-methyl-carbamoyl}-2-naphthalen-2-yl-ethyl)-methyl-carbamoyl]-1,1-dimethyl-but-3-enyl}-carbamic acid tert-butyl ester
• 英文别名: tert-butyl N-[(E)-6-[[(2R)-1-[[(2R)-1-(2,2-dimethylhydrazinyl)-1-oxo-3-thiophen-2-ylpropan-2-yl]-methylamino]-3-naphthalen-2-yl-1-oxopropan-2-yl]-methylamino]-2-methyl-6-oxohex-4-en-2-yl]carbamate
• CAS: 232615-24-6
• 化学式: C₃₆H₄₉N₅O₅S
• 分子量: 663.882
• InChiKey: DJXWEKZUWMXSDE-ORYCTFIOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.8
• 重原子数：
  47
• 可旋转键数：
  15
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  140
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  {(E)-4-[((R)-1-{[(R)-1-(N',N'-Dimethyl-hydrazinocarbonyl)-2-thiophen-2-yl-ethyl]-methyl-carbamoyl}-2-naphthalen-2-yl-ethyl)-methyl-carbamoyl]-1,1-dimethyl-but-3-enyl}-carbamic acid tert-butyl ester 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 生成 NNC 26-1137
  参考文献：
  名称：

  Growth hormone secretagogues derived from NN703 with hydrazidesas c-terminal

  摘要：

  A series of GH secretagogues based on modifications in the C-terminal of NN703 is reported. The C-terminal N-methyl amide of NN703 has been replaced with alkylated hydrazides in order to decrease the volume of distribution and identify GH secretagogues with shorter duration of action. Most of the prepared compounds show high potency in a rat pituitary assay. Subsequent to an initial in vivo screening in dogs, four compounds were selected for further pharmacological and pharmacokinetic evaluation. The four compounds showed oral bioavailability around 35% and equipotency in vitro compared to NN703. The relationship between lipophilicity and volume of distribution is discussed and it is speculated whether the lower volume of distribution is attributed to the observed higher in vivo potency and shorter plasma elimination half-life. (C) 2000 Editions scientifiques et medicales Elsevier SAS.

  DOI：

  10.1016/s0223-5234(00)00146-x
• 作为产物：
  描述：

  (alphaR)-alpha-[[(1,1-二甲基乙氧基)羰基]甲基氨基]-2-萘丙酸 在 N-羟基-7-氮杂苯并三氮唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 生成 {(E)-4-[((R)-1-{[(R)-1-(N',N'-Dimethyl-hydrazinocarbonyl)-2-thiophen-2-yl-ethyl]-methyl-carbamoyl}-2-naphthalen-2-yl-ethyl)-methyl-carbamoyl]-1,1-dimethyl-but-3-enyl}-carbamic acid tert-butyl ester
  参考文献：
  名称：

  Growth hormone secretagogues derived from NN703 with hydrazidesas c-terminal

  摘要：

  A series of GH secretagogues based on modifications in the C-terminal of NN703 is reported. The C-terminal N-methyl amide of NN703 has been replaced with alkylated hydrazides in order to decrease the volume of distribution and identify GH secretagogues with shorter duration of action. Most of the prepared compounds show high potency in a rat pituitary assay. Subsequent to an initial in vivo screening in dogs, four compounds were selected for further pharmacological and pharmacokinetic evaluation. The four compounds showed oral bioavailability around 35% and equipotency in vitro compared to NN703. The relationship between lipophilicity and volume of distribution is discussed and it is speculated whether the lower volume of distribution is attributed to the observed higher in vivo potency and shorter plasma elimination half-life. (C) 2000 Editions scientifiques et medicales Elsevier SAS.

  DOI：

  10.1016/s0223-5234(00)00146-x

文献信息

• Compounds with growth hormone releasing properties
  申请人：NOVO NORDISK A/S

  公开号：EP1506969A1

  公开（公告）日：2005-02-16

  Compounds of the general formula I and their use for treating medical disorders resulting from a deficiency in growth hormone.

  通式 I 的化合物 以及它们在治疗因生长激素缺乏而引起的疾病方面的用途。
• COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES
  申请人：NOVO NORDISK A/S

  公开号：EP1047709B1

  公开（公告）日：2004-11-03